Colomban, O;
Tod, M;
Peron, J;
Perren, TJ;
Leary, A;
Cook, AD;
Sajous, C;
... You, B; + view all
(2021)
Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7).
JNCI Cancer Spectrum
, 4
(3)
, Article pkaa026. 10.1093/JNCICS/PKAA026.
Preview |
Text
pkaa026.pdf - Published Version Download (847kB) | Preview |
Abstract
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA- 125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0 (n=214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n=244, 53.2%) derived the highest OS benefit (absolute difference = 9.1 months, 2-sided log-rank P=.10; Cox hazard ratio = 0.78, 95% confidence interval = 0.58 to 1.04, 2-sided P=.09).
| Type: | Article |
|---|---|
| Title: | Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7) |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/JNCICS/PKAA026 |
| Publisher version: | http://dx.doi.org/10.1093/JNCICS/PKAA026 |
| Language: | English |
| Additional information: | © The Author(s) 2020. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | chemotherapy regimen, ca-125 antigen, phase 3 clinical trials, kinetics, neoplasms, ovarian cancer, bevacizumab, elimination rate constant, progression-free survival, datasets |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10123745 |
Archive Staff Only
 |
View Item |
